109173 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
MicroRNA-328 anti-sense composition and therapeutic use
#902Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#903Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof
#904Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#905COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS
#906Micromirs
#907Pharmaceutical Composition
#908Arrays of memory cells individually comprising a capacitor and an elevationally-extending transistor, methods of forming a tier of an array of memory cells, and methods of forming an array of memory cells individually comprising a capacitor and an elevationally-extending transistor
#909CRISPR-BASED COMPOSITIONS AND METHODS OF USE
#910Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
#911Targeting microRNAs for metabolic disorders
#912Allele specific modulators of P23H rhodopsin
#913MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#914Tau antisense oligomers and uses thereof
#915MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
#916MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#917Methods for modulating expression of C9ORF72 antisense transcript
#918Modified oligonucleotides and methods of use
#919Stabilized STAT3 decoy oligonucleotides and uses therefor
#920Modulation of nuclear-retained RNA
#921BIVALENT ANTISENSE OLIGONUCLEOTIDES
#922ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN
#923MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
#924Antisense compounds targeting genes associated with cystic fibrosis
#925REGULATION OF MIR-33 MICRORNAS IN THE TREATMENT OF CHOLESTEROL-RELATED DISORDERS
#926Compositions for modulating expression of C9ORF72 antisense transcript
#927Targeting hepatitis B virus (HBV) host factors
#928Stereospecific Phosphorothioate LNA
#929Segmented micro RNA mimetics
#930CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS
#931Compounds and methods for modulating TMPRSS6 expression
#932Short interfering nucleic acid (siNA) compositions
#933Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
#934Inhibitors of MYH7B and uses thereof
#935MODIFIED TGF-BETA2 OLIGONUCLEOTIDES
#936Micro-RNA inhibitors and their uses in disease
#937Chimeric double-stranded nucleic acid
#938Modulation of alpha synuclein expression
#939RNA products and uses thereof
#940Assay for telomere length regulators
#941siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof
#942Compositions and methods for inhibition of nucleic acids function
#943COMPOSITIONS AND METHODS FOR MODULATING RNA
#944Therapeutic nanoparticles and methods of use thereof
#945Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#946INHIBITORS OF MIR-17-92 CLUSTER FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA AND OTHER MALIGNANCIES
#947Compositions and methods for modulating Tau expression
#948Guide RNA with chemical modifications
#949Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
#950Compositions and methods for modulating TTR expression
#951Oligonucleotide compositions and uses thereof
#952Short interfering RNA for treating cancer
#953TARGETING OLIGONUCLEOTIDES AND USES THEREOF TO MODULATE GENE EXPRESSION
#954Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers
#955Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
#956Oligomers Having Bicyclic Scaffold Moeities
#957MICRORNAS IN NEURODEGENERATIVE DISORDERS
#958LNA OLIGONUCLEOTIDES WITH ALTERNATING FLANKS
#959Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
#960Compositions for modulating expression of C9ORF72 antisense transcript
#961Antisense conjugates for decreasing expression of DMPK
#962LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate Linkages
#963Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#964ANTISENSE COMPOUNDS AND USES THEREOF
#965Antisense oligonucleotides for modulating HTRA1 expression
#966COMPOSITIONS AND METHODS
#967MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#968EGFR nucleic acids and uses thereof
#969Modulation of UBE3A-ATS expression
#970Treatment and prevention of thrombosis using an anti-miR
#971Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#972Compositions for modulating C9ORF72 expression
#973RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#974Antisense design
#975Antisense design
#976Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
#977ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#978Chiral library screen
#979Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#980Decoy oligonucleotides for the treatment of diseases
#981Selective Reactivation of Genes on the Inactive X Chromosome
#982Modulation of AGPAT5 expression
#983Antisense-oligonucleotides as inhibitors of TGF-R signaling
#984Modulation of prekallikrein (PKK) expression
#985Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
#986Oligonucleotide targeted to the A20-3′ untranslated region
#987RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#988Enhancing dermal wound healing by downregulating microRNA-26a
#989KRAS nucleic acids and uses thereof
#990ANTISENSE COMPOUNDS AND USES THEREOF
#991Downregulating miR-132 for the treatment of lipid related disorders
#992Antisense design
#993Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
#994Modified double-stranded RNA agents
#995Methods of Inducing Exon Skipping
#996METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
#997Methods and pharmaceutical compositions for treatment of cystic fibrosis
#998Methods of Inducing Exon Skipping
#999Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1000ANTISENSE COMPOUNDS AND USES THEREOF
#1001Modified antimir-138 oligonucleotides
#1002Tricyclo-DNA antisense oligonucleotides, compositions, and methods for the treatment of disease
#1003Allele-specific therapy for huntington disease haplotypes
#1004Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
#1005RAS exon 2 skipping for cancer treatment
#1006Polynucleotide agents targeting Serpinc1 (AT3) and methods of use thereof
#1007MicroRNA compounds and methods for modulating miR-21 activity
#1008BIOLOGICALLY ACTIVE NUCLEOTIDE MOLECULES FOR SELECTIVELY KILLING OFF CELLS, USE THEREOF, AND APPLICATION KIT
#1009Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
#1010REGULATION OF MIR-33 MICRORNAS IN THE TREATMENT OF CHOLESTEROL-RELATED DISORDERS
#1011TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#1012COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES
#1013MicroRNA compounds and methods for modulating miR-122
#1014Targeting microRNAs for metabolic disorders
#1015Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene
#1016OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY
#1017Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
#1018Multimetric oligonucleotide compounds
#1019Antisense oligonucleotide compositions
#1020Oligonucleotide comprising an inosine for treating DMD
#1021Targeting human satellite II (HSATII)
#1022Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#1023Antisense compounds targeting apolipoprotein E receptor 2
#1024Oligonucleotides for inducing paternal UBE3A expression
#1025Blocking Hepatitis C Virus infection associated liver tumor development with HCV-specific antisense RNA
#1026Exosomal loading using hydrophobically modified oligonucleotides
#1027Antisense compounds
#1028Exon skipping technology in VCP disease
#1029Compositions for modulating Ataxin 2 expression
#1030Methods for modulating Ataxin 2 expression
#1031MIR-21-3P INHIBITORS IN SKIN DISORDERS
#1032Compositions and methods for modulating growth hormone receptor expression
#1033Methods of treating fragile X syndrome and related disorders
#1034Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#10355' TARGETING OLIGONUCLEOTIDES FOR MODULATING RNA
#1036Cancer treatment
#1037Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
#1038Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
#1039Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
#1040Nucleic acid drug for inducing skipping of variant exon of CD44 gene and increasing expression of normal type CD44 mRNA
#1041LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF
#1042Methods and compositions for modulating apolipoprotein (a) expression
#1043METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#1044Compounds and methods for trans-membrane delivery of molecules
#1045Diagnosis and treatment of Friedreich's ataxia
#1046Compounds and methods for enhanced cellular uptake
#1047Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling
#1048METHODS AND COMPOSITIONS FOR INCREASING EFFICIENCY OF TARGETED GENE MODIFICATION USING OLIGONUCLEOTIDE-MEDIATED GENE REPAIR
#1049Targeting hepatitis B virus (HBV) host factors
#1050Modulation of TMPRSS6 expression
#1051Treatment for conditions associated with fibrosis and collagen deposition
#1052Targeting microRNAs for metabolic disorders
#1053Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
#1054Polycomb-associated non-coding RNAs
#1055Oligomeric compounds comprising alpha-beta-constrained nucleic acid
#1056CRISPR-based compositions and methods of use
#1057CRISPR-based compositions and methods of use
#1058METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#1059tRNA derived small RNAs (tsRNAs) involved in cell viability
#1060Linkage modified oligomeric compounds
#1061Methods targeting miR-128 for regulating cholesterol/lipid metabolism
#1062Compositions for modulating SOD-1 expression
#1063MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#1064Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1065SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE
#1066RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
#1067Polycomb-associated non-coding RNAs
#1068RNA interference in skin indications
#1069Short interfering RNA (siRNA) analogues
#1070Compositions and methods for inhibition of nucleic acids function
#1071Inhibition of NEAT1 for treatment of solid tumors
#1072SiRNA targeting PRK2, which is hepatitis C virus therapeutic agent
#1073Modulation of prekallikrein (PKK) expression
#1074Methods and Compositions Related To miR-21 and miR-29A, Exosome Inhibition And Cancer Metastasis
#1075Polycomb-associated non-coding RNAS
#1076Molecular re-engineering of excitation-inhibition balance in memory circuits
#1077Compositions and their uses directed to huntingtin
#1078COMPOSITIONS AND METHODS OF USING MICRORNA INHIBITORS
#1079Methods and compositions for modulating alpha-1 antitrypsin expression
#1080Potent LNA oligonucleotides for the inhibition of HIF-1A expression
#1081miR-29 mimics and uses thereof
#1082miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
#1083Polycomb-associated non-coding RNAs
#1084MicroRNA-Based Methods and Assays for Osteosarcoma
#1085Polycomb-associated non-coding RNAs
#1086Antisense design
#1087Compounds of chemically modified oligonucleotides and methods of use thereof
#1088Modulation of signal transducer and activator of transcription 3 (STAT3) expression
#1089MICRORNA MODULATION OF ARTHEROSCLEROSIS AND USES THEREOF
#1090MicroRNA compounds and methods for modulating miR-21 activity
#1091Oligonucleotide-based inhibitors comprising locked nucleic acid motif
#1092Non-coding RNA of and identification and use thereof
#1093Multiplex guide RNAs
#1094COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#1095MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS
#1096Interferon Regulatory Factor 1 (IRF1) Decoys and Methods of Use Thereof
#1097USE OF MICRORNA 146-A IN THE DIAGNOSIS, TREATMENT AND PREVENTION OF PICORNAVIRUS INFECTION AND MICRORNA 146-A ANTAGONISTS
#1098Guide RNA with chemical modifications
#1099METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
#1100Targeting microRNA-26a/b for the treatment of neurodegenerative disease
#1101OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD
#1102RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#1103MicroRNA compounds and methods for modulating miR-122
#1104MicroRNAs modulating the effect of glucocorticoid signaling
#1105Compositions for modulating C9ORF72 expression
#1106Antisense compounds targeting genes associated with cystic fibrosis
#1107Reduced size self-delivering RNAI compounds
#1108RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1109Modular RNA regulators and methods
#1110METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#1111Tau antisense oligomers and uses thereof
#1112siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof
#1113POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION
#1114Compositions and methods for treating amyotrophic lateral sclerosis
#1115Methods and pharmaceutical compositions for treatment of cystic fibrosis
#1116MODULATORS OF COMPLEMENT FACTOR B
#1117Antisense-induced exon2 inclusion in acid alpha-glucosidase
#1118Targeting microRNAs for metabolic disorders
#1119miR-92 inhibitors and uses thereof
#1120Therapeutic agent for corneal epithelial disorder
#1121COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF FRATAXIN
#1122Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
#1123Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
#1124NEW CELL-SPECIFICALLY ACTIVE NUCLEOTIDE MOLECULES AND APPLICATION KIT FOR THE APPLICATION THEREOF
#1125Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
#1126Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
#1127CRISPR-based compositions and methods of use
#1128Channel modulators
#1129ANTISENSE DESIGN
#1130ANTISENSE DESIGN
#1131Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
#1132UNA single stranded oligomers for therapeutics
#1133Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
#1134Oligomers with improved off-target profile
#1135Double-stranded agents for delivering therapeutic oligonucleotides
#1136Compositions, kits and methods for treatment of cardiovascular,immunological and inflammatory diseases
#1137Antisense-oligonucleotides as inhibitors of TGF-R signaling
#1138Oligonucleotide conjugates
#1139Anti-miR-27b and anti-miR-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases
#1140Microrna compounds and methods for modulating MIR-21 activity
#1141Double-stranded antisense nucleic acid with exon-skipping effect
#1142OLIGONUCLEOTIDE MODULATORS OF B-CELL CLL/LYMPHOMA 11A (BCL11A) AND USES THEREOF
#1143Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
#1144COMPOSITIONS AND METHODS FOR MODULATING FOXP3 EXPRESSION
#1145SiRNA targeting HSR1
#1146Hydrophobically modified antisense oligonucleotides comprising a ketal group
#1147Targeting microRNAs for the treatment of fibrosis
#1148OLIGOMERS TARGETING HEXANUCLEOTIDE REPEAT EXPANSION IN HUMAN C9ORF72 GENE
#1149CHIMERIC SINGLE-STRANDED ANTISENSE POLYNUCLEOTIDES AND DOUBLE-STRANDED ANTISENSE AGENT
#1150NEUROTENSIN-INDUCED TUMOR FORMATION IS REGULATED BY MICRO RNA 133A-AFTIPHILIN-DEPENDENT RECEPTOR RECYCLING
#1151Sequence conversion and signal amplifier DNA having locked nucleic acids and detection methods using same
#1152Antisense compounds and uses thereof
#1153Compositions and methods for modulating apolipoprotein (a) expression
#1154Compositions and methods for modulating apolipoprotein C-III expression
#1155Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
#1156Modified TGF-beta oligonucleotides
#1157Compositions and methods
#1158Compositions and methods for modulating HBV expression
#1159Compositions and methods for modulation nucleic acids through nonsense mediated decay
#1160Modulation of androgen receptor expression
#1161Modulation of dystrophia myotonica-protein kinase (DMPK) expression
#1162miR-29 mimics and uses thereof
#1163Modified TGF-beta2 oligonucleotides
#1164MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#1165RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1166Genome editing using effector oligonucleotides for therapeutic treatment
#1167Modulation of hepatitis B virus (HBV) expression
#1168Aptamer to IL-17 and use thereof
#1169Targeting microRNAs for metabolic disorders
#1170Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
#1171Oligonucleotides for modulating gene expression and uses thereof
#1172Modulation of RNA activity and vascular permeability
#1173Oral delivery of therapeutically effective LNA oligonucleotides
#1174Inhibitors of MYH7B and uses thereof
#1175Compositions and methods for modulating Tau expression
#1176Methods for monitoring C9ORF72 expression
#1177LNA antisense oligonucleotides for the modulation of Myc expression
#1178Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1179Oligomers and oligomer conjugates
#1180Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
#1181Locked nucleic acid inhibitor of miR-145 and uses thereof
#1182Bridged bicyclic nucleosides
#1183Method for treating and/or preventing myopia
#1184Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
#1185ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
#1186METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS
#1187Cancer treatment
#1188Selective antisense compounds and uses thereof
#1189Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
#1190Segmented micro RNA mimetics
#1191LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES
#1192Inhibitors of miRNAs 221 and 222 for anti-tumor activity in multiple myeloma
#1193Oligonucleotides for modulation of target RNA activity
#1194Compounds and methods for modulating gene expression
#1195Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1196SELECTIVE REDUCTION OF ALLELIC VARIANTS
#1197Oligomeric compounds and compositions for the use in modulation of micrornas
#1198Antisense modulation of PTP1B expression
#1199Compositions and Methods for Modulation of ATXN3 Expression
#1200NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF